Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Jalal Dahham, Rana Rizk, Mickaël Hiligsmann, Caroline Daccache, Samia J. Khoury, Hala Darwish, Silvia Evers & Ingrid Kremer. (2022) The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol. Expert Review of Pharmacoeconomics & Outcomes Research 22:5, pages 869-876.
Read now
Read now
Dirk Schriefer, Rocco Haase, Nils-Henning Ness & Tjalf Ziemssen. (2022) Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 177-195.
Read now
Read now
Yaling Du, Rui Min, Xiaoyan Zhang & Pengqian Fang. (2021) Factors associated with the healthcare expenditures of patients with multiple sclerosis in urban areas of China estimated by a generalized estimating equation. Expert Review of Pharmacoeconomics & Outcomes Research 21:1, pages 137-144.
Read now
Read now
Timo Purmonen, Tanja Hakkarainen, Melina Tervomaa & Juhani Ruutiainen. (2020) Impact of multiple sclerosis phenotypes on burden of disease in Finland. Journal of Medical Economics 23:2, pages 156-165.
Read now
Read now
M. A. Piena, M. Heisen, L. W. Wormhoudt, J. van Wingerden, S. T. F. M. Frequin & B. M. J. Uitdehaag. (2018) Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. Journal of Medical Economics 21:10, pages 968-976.
Read now
Read now
Juhani Ruutiainen, Anna-Mari Viita, Jarmo Hahl, Jesse Sundell & Helena Nissinen. (2016) Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis. Journal of Medical Economics 19:1, pages 21-33.
Read now
Read now
Ewa Stawowczyk, Krzysztof Piotr Malinowski, Paweł Kawalec & Paweł Moćko. (2015) The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research 15:5, pages 759-786.
Read now
Read now
Articles from other publishers (26)
Izumi Kawachi, Hiromichi Otaka, Kosuke Iwasaki, Tomomi Takeshima & Kengo Ueda. (2022) Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis. Neurology and Therapy 11:3, pages 1253-1268.
Crossref
Crossref
Izumi Kawachi, Hiromichi Otaka, Kosuke Iwasaki, Tomomi Takeshima & Kengo Ueda. (2022) A Principal Component Analysis Approach to Estimate the Disability Status for Patients with Multiple Sclerosis Using Japanese Claims Data. Neurology and Therapy 11:1, pages 385-396.
Crossref
Crossref
Hasnat Ahmad, Ingrid van der Mei, Bruce Taylor, Ting Zhao, Qing Xia & Andrew J. Palmer. (2021) Does health-related quality of life differ between people with relapse onset and progressive onset Multiple Sclerosis?. Multiple Sclerosis and Related Disorders 54, pages 103138.
Crossref
Crossref
Jalal Dahham, Rana Rizk, Ingrid Kremer, Silvia M. A. A. Evers & Mickaël Hiligsmann. (2021) Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review. PharmacoEconomics 39:7, pages 789-807.
Crossref
Crossref
Selin KALENDER & Vahit YİĞİT. (2021) Multipl Skleroz Hastalığının Engellilik Seviyesine Göre Maliyetleri: Sistematik Derleme ÇalışmasıCosts of Multiple Sclerosis According to the Level of Disability: A Systematic Review Study. Arşiv Kaynak Tarama Dergisi 30:2, pages 101-118.
Crossref
Crossref
Jacqueline Nicholas, Huanxue Zhou & Chinmay Deshpande. (2020) Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis. Advances in Therapy.
Crossref
Crossref
Ingrid E. H. Kremer, Mickael Hiligsmann, Josh Carlson, Marita Zimmermann, Peter J. Jongen, Silvia M. A. A. Evers, Svenja Petersohn, Xavier G. L. V. Pouwels & Nick Bansback. (2020) Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. Medical Decision Making 40:8, pages 1003-1019.
Crossref
Crossref
Hasnat Ahmad, Ingrid van der Mei, Bruce V. Taylor, Julie A. Campbell & Andrew J. Palmer. (2020) Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument. Multiple Sclerosis and Related Disorders 44, pages 102358.
Crossref
Crossref
Maria Paz-Zulueta, Paula Parás-Bravo, David Cantarero-Prieto, Carla Blázquez-Fernández & Agustín Oterino-Durán. (2020) A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.. Multiple Sclerosis and Related Disorders 43, pages 102162.
Crossref
Crossref
Martina Petruzzo, Raffaele Palladino, Antonio Nardone, Agostino Nozzolillo, Giuseppe Servillo, Valentina Orlando, Marcello De Angelis, Roberta Lanzillo, Vincenzo Brescia Morra & Marcello Moccia. (2020) The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 38, pages 101514.
Crossref
Crossref
Jacqueline A. Nicholas, Batul Electricwala, Lulu K. Lee & Kristen M. Johnson. (2019) Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data. BMC Neurology 19:1.
Crossref
Crossref
Renée Else Michels, Maria de Fransesco, Koshu Mahajan, Gerald J. D. Hengstman, Krijn M. H. Schiffers, Sangeeta Budhia, Gerard Harty & Marieke Krol. (2019) Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Applied Health Economics and Health Policy 17:6, pages 857-873.
Crossref
Crossref
Servaas Buijs, Marieke Krol & Gert de Voer. (2018) Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study. Journal of Comparative Effectiveness Research 7:5, pages 453-462.
Crossref
Crossref
LARA GITTO. 2017. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis
17
37
.
Hasnat Ahmad, Bruce V Taylor, Ingrid van der Mei, Sam Colman, Beth A O’Leary, Monique Breslin & Andrew J Palmer. (2016) The impact of multiple sclerosis severity on health state utility values: Evidence from Australia. Multiple Sclerosis Journal 23:8, pages 1157-1166.
Crossref
Crossref
M. Moccia, R. Palladino, R. Lanzillo, M. Triassi & V. Brescia Morra. (2017) Predictors of the 10-year direct costs for treating multiple sclerosis. Acta Neurologica Scandinavica 135:5, pages 522-528.
Crossref
Crossref
Erkki Soini, Jaana Joutseno & Marja-Liisa Sumelahti. (2017) Cost-utility of First-line Disease-modifying Treatments for Relapsing–Remitting Multiple Sclerosis. Clinical Therapeutics 39:3, pages 537-557.e10.
Crossref
Crossref
Marcello Moccia, Raffaele Palladino, Roberta Lanzillo, Antonio Carotenuto, Cinzia Valeria Russo, Maria Triassi & Vincenzo Brescia Morra. (2017) Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015. PLOS ONE 12:1, pages e0169489.
Crossref
Crossref
Gavin Giovannoni, Helmut Butzkueven, Suhayl Dhib-Jalbut, Jeremy Hobart, Gisela Kobelt, George Pepper, Maria Pia Sormani, Christoph Thalheim, Anthony Traboulsee & Timothy Vollmer. (2016) Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders 9, pages S5-S48.
Crossref
Crossref
Olivia Ernstsson, Hanna Gyllensten, Kristina Alexanderson, Petter Tinghög, Emilie Friberg & Anders Norlund. (2016) Cost of Illness of Multiple Sclerosis - A Systematic Review. PLOS ONE 11:7, pages e0159129.
Crossref
Crossref
Turhan Kahraman, Sema Savci, Esra Coskuner-Poyraz, Serkan Ozakbas & Egemen Idiman. (2015) Determinants of physical activity in minimally impaired people with multiple sclerosis. Clinical Neurology and Neurosurgery 138, pages 20-24.
Crossref
Crossref
Zhu Xu, Feng Zhang, FangLi Sun, KeFeng Gu, Shuai Dong & Dian He. (2015) Dimethyl fumarate for multiple sclerosis. Cochrane Database of Systematic Reviews 2015:4.
Crossref
Crossref
Marita P McCabe, Katherine J Ebacioni, Rex Simmons, Elizabeth McDonald & Lisa Melton. (2015) Unmet education, psychological and peer support needs of people with multiple sclerosis. Journal of Psychosomatic Research 78:1, pages 82-87.
Crossref
Crossref
Emer Fogarty, Cathal Walsh, Christopher McGuigan, Niall Tubridy & Michael Barry. (2014) Direct and Indirect Economic Consequences of Multiple Sclerosis in Ireland. Applied Health Economics and Health Policy 12:6, pages 635-645.
Crossref
Crossref
K. O׳Connell, S.B. Kelly, E. Fogarty, M. Duggan, L. Buckley, M. Hutchinson, C. McGuigan & N. Tubridy. (2014) Economic costs associated with an MS relapse. Multiple Sclerosis and Related Disorders 3:6, pages 678-683.
Crossref
Crossref
Zhu Xu, Feng Zhang, FangLi Sun, KeFeng Gu, Shuai Dong & Dian He. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.